Phase 2 N=53 Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ovarian Cancer
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 3; 4; 6; 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…
Phase 2 N=60 Multi OIT to Test Immune Markers After Minimum Maintenance Dose
Food Allergy
Primary: Change in Allergen-specific Serum IgG4 and IgE — 578.5; 738.5 Total serum IgE (kU/L)
Phase 2 N=125 Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Primary: Overall Survival (OS) — 9.7; 7.8 months — p=0.1800
Phase 2 N=20 Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
Tinea Pedis
Primary: Number of Participants With Complete Cure: Post Treatment (Day 17) — 0; 4 Participants
Phase 2 N=124 An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Proportion of Overall Responders — 7; 10; 12; 7 Participants
Phase 2 N=40 Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Leukemia
Primary: Progression Free Survival (PFS) — 45 Months
Phase 2 N=30 Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy
Breast Cancer
Primary: PBMC NF-kB DNA Binding Measured in ng/Well — 9.01; 9.56; 17.54; 16.04 ng/well
Phase 2 N=35 Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stomach Cancer · Gastric (Stomach) Cancer · Neoplasm of Cardioesophageal Junction
Primary: Progression-Free Survival (PFS) — 9 Participants
Phase 2 N=81 Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Human Papillomavirus Infection · Stage I Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma
Primary: 2-year Loco-regional Tumor Control (LRC) Rate — 100; 93; 96.2 percentage of patients
Phase 2 N=26 Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
HIV Infections
Primary: Termination From Treatment Due to a Suspected Adverse Drug Reaction (SADR) — 1; 0; 10; 4 Participants
Phase 2 N=58 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Proportion of Participants With Objective Response — 0.196 Proportion of participants
Phase 2 N=77 Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Erythropoietic Protoporphyria
Primary: Time in Direct Sunlight Between 10:00-15:00 on Pain-free Days — 8.25; 0.75 Hours
Phase 2 N=32 Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
CD30 Positive Primary Mediastinal Large B-cell Lymphoma · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30-Positive Gray Zone Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
Phase 2 N=32 Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Small Lymphocytic Lymphoma · CLL (Chronic Lymphocytic Leukemia)
Primary: Progression Free Survival Rate 2 Years After Initiation of Induction Therapy — 14; 9 Participants